ITHAX Acquisition Corp III Announces Closing of $230 Million Initial Public Offering
Notified -
Globe Newswire16-12-2025, 04:01
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC 9-08-2025, 02:25